Source comparison
PT-141 vs Vyleesi Mechanism: Full Comparison
Active Ingredient Bremelanotide (cyclic heptapeptide) Identical molecular mechanism Mechanism of Action MC4R agonist in hypothalamus Same central pathway activation Regulatory Status Research chemical, no FDA drug approval FDA-approved under NDA 211460 Vyleesi
This comparison does not assign a generated winner or score.
- Active Ingredient
- Bremelanotide (cyclic heptapeptide)
- Identical molecular mechanism
- Mechanism of Action
- MC4R agonist in hypothalamus
- Same central pathway activation
- Regulatory Status
- Research chemical, no FDA drug approval
- FDA-approved under NDA 211460
- Vyleesi has clinical trial validation, PT-141 does not
- Delivery Format
- Lyophilised powder requiring reconstitution
- Pre-filled 1.75mg autoinjector
- Vyleesi eliminates user dosing error
- Dosing Precision
- User-measured (0.5–2mg typical range)
- Fixed 1.75mg per injection
- PT-141 dosing variability increases nausea risk
- Batch Testing
- Manufacturer-dependent, no federal oversight
- FDA-mandated potency/purity testing
- Vyleesi guarantees consistent product quality
- Half-Life
- ~2.7 hours (subcutaneous)
- Pharmacokinetics identical
- Clinical Efficacy Data
- No Phase III trials under PT-141 name
- RECONNECT trials: 25% response vs 17% placebo
- Vyleesi efficacy is peer-reviewed and published